Actively Recruiting
Comparison of Partial Stomach-Partitioning and Conventional Gastrojejunostomy for the Treatment of Gastric Outlet Obstruction in Advanced Gastric Cancer
Led by Guangxi Medical University · Updated on 2026-05-01
80
Participants Needed
1
Research Sites
156 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The primary goal of clinical treatment is to relieve obstruction, restore oral feeding, improve nutritional status and improve quality of life in patients with advanced gastric cancer outflow tract obstruction. At present, the common surgical treatment for relieving obstruction is traditional gastrojejunostomy. Although the operation can relieve the obstruction, there are problems such as tumor-induced bleeding, anastomotic invasion, and high incidence of delayed gastric emptying after operation. Partitioned gastrojejunostomy effectively relieves obstruction by anastomosis of a part of the stomach to the jejunum, and isolates the tumor from the anastomosis, which is beneficial to food emptying and can reduce the risk of bleeding and anastomotic invasion. The safety and efficacy of these two procedures are still controversial, mainly because previous studies were retrospective studies or included a small sample size or enrolled patients with different pathological characteristics. The purpose of this study was to compare the safety and efficacy of separated and traditional gastrojejunostomy in the treatment of advanced gastric cancer outflow tract obstruction, and to provide the best choice for the treatment of advanced gastric cancer outflow tract obstruction.
CONDITIONS
Official Title
Comparison of Partial Stomach-Partitioning and Conventional Gastrojejunostomy for the Treatment of Gastric Outlet Obstruction in Advanced Gastric Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients and their families fully understand the study and have signed informed consent
- Age between 18 and 75 years old
- Diagnosed with distal gastric cancer (clinical stage T4bN+ M0 / T3-4N+ M1, stage IV) that is locally unresectable or has distant/peritoneal metastasis
- Have digestive tract obstruction confirmed by upper gastrointestinal radiography or gastroscopy, with GOOSS score of 1 or less
- ECOG score between 0 and 2 with no deterioration within 7 days
- ASA physical status classification I to III
- No prior anti-tumor treatments such as radiotherapy, chemotherapy, targeted therapy, or immunotherapy
- Adequate organ function including specified blood counts, liver, kidney, and heart function
- Women of childbearing age must use effective contraception
- No other surgical contraindications
- Good compliance and willingness to follow up
You will not qualify if you...
- Unable to follow the research procedures or program
- History of other malignant tumors within 5 years except certain skin cancers or cervical carcinoma in situ
- Active or recent autoimmune diseases within 4 weeks prior to enrollment
- Previous allogeneic bone marrow or organ transplant
- Significant cardiovascular diseases including recent heart attack, severe angina, heart failure (NYHA grade >2), ventricular arrhythmia requiring medication, or left ventricular ejection fraction below 50%
- Active or uncontrolled severe infection (grade 2 or higher)
- Known HIV infection or active viral hepatitis B or C
- Pregnant or breastfeeding women
- Any other significant metabolic, physical, or laboratory abnormalities that may interfere with study or patient safety
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Guangxi Medical University Cancer Hospital
Nanning, Guangxi, China, 530021
Actively Recruiting
Research Team
Y
Yuzhou Qin
CONTACT
L
Liucheng Wu
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here